ABA Clinics Are Bringing Autism Diagnosis In-House to Get Kids Into Therapy Faster

A Trend Taking Shape

Traditionally, many ABA clinics focused only on therapy. A family arrived with a diagnosis already in hand, usually from an outside clinician, and the clinic took it from there. That arrangement is changing. A growing number of ABA therapy providers are now adding their own autism diagnostic evaluations rather than relying entirely on outside clinicians.

The shift is visible in how providers describe and structure their services. Acorn Health, ABA Centers of America, Hopebridge and InBloom now advertise diagnostic evaluations alongside ABA therapy. For families, the appeal is a more direct route from concern to evaluation and, when clinically appropriate, treatment. For operators, adding diagnostics also brings more of the intake pathway inside the same organization.

Who Is Doing It

The clearest example right now is Acorn Health, a chain of more than 70 centers backed by the Ontario Teachers’ Pension Plan. Acorn expanded its in-house diagnostic evaluations to Tampa and Orlando in June 2026 and announced that it would begin offering them in Nashville in July, in addition to programs it was already running in Michigan. Licensed psychologists conduct the evaluations, which are available to children as young as 18 months. The company’s chief clinical officer said families are often waiting too long for answers.

The pattern skews toward the larger, capital-backed chains, which makes sense because they can afford to staff psychologists and absorb the setup cost that kept smaller clinics out of diagnosis in the first place.

Why Now: Access, Capital and Staffing

Two things are driving this at the same time. The first is a real access problem. Studies and provider reports describe evaluation delays lasting many months and, in some systems, more than a year. In the CDC’s 2022 surveillance data, the median age of earliest known autism diagnosis among 8-year-olds was 47 months, even though recommended autism screening at 18 and 24 months and diagnosis by an experienced professional can be reliable by age 2. The CDC now estimates prevalence at one in 31 among 8-year-olds. That gap is what in-house diagnostic lines are intended to narrow.

The second driver is a fast-growing market that is attracting investor capital. Mordor Intelligence estimates the global ABA market at $8.33 billion in 2026 and projects it will reach $10.39 billion by 2031. That growth helps explain why capital-backed chains are among the providers building diagnosis into their operations.

The operational enabler is staffing. Providers such as Acorn say their diagnostic evaluations are conducted by licensed psychologists or other qualified diagnosticians, allowing ABA companies to add evaluations without employing a large developmental-pediatrics team. That model still requires professional oversight and does not make diagnosis part of a BCBA’s ordinary scope of practice.

The Pushback: Self-Referral and Scope of Practice

The recurring concern is a built-in conflict of interest in the model. If a clinic diagnoses a child and then immediately recommends 40 hours a week of its own therapy, that recommendation can start to look like a sales decision rather than a clinical one. The worry is self-referral, and it is the flagged risk that runs through nearly every account of this trend.

Related concerns follow from it. There is a scope-of-practice concern, since autism diagnosis is not part of a BCBA’s ordinary professional role and complex differential diagnosis may require a qualified psychologist, physician, or other authorized clinician, depending on state law and payer rules. And there is confirmation bias, the pull toward findings that feed the therapy pipeline. Notably, the operators themselves emphasize licensed-psychologist or qualified-diagnostician evaluations and ABA-when-warranted language, which reads as a direct response to exactly this criticism.

AT A GLANCE

SOURCES & REFERENCES